NanoLogix Applauds Energy Bill Signing

Aug 12, 2005, 01:00 ET from NanoLogix, Inc.

    SHARON, Pa., Aug. 12 /PRNewswire-FirstCall/ -- NanoLogix, Inc.,
 (Pink Sheets:   NNLX), a Nano-biotechnology company engaged in the research,
 development and commercialization of technologies for alternative sources of
 fuel, the production of bacteria and disease testing kits, cancer therapy and
 remediation of toxic materials announced today that the recent signing of the
 energy bill, passed by Congress and signed by the President, should provide an
 opportunity for NanoLogix to demonstrate its recent developments in hydrogen
 generation systems.
     NanoLogix's recent agreement to generate hydrogen from a NanoLogix
 scale-up bioreactor system using Arrowhead Wine Cellar's waste organic matter
 is the company's first scale-up unit installation providing valuable data for
 engineered systems.
     The signing of the bill helps companies like NanoLogix diversify our
 national energy supply by promoting alternative and renewable energy sources.
 Hydrogen, which is clean burning, has great potential in hydrogen-powered
 automobiles, industrial and other uses toward a more affordable and reliable
 energy future for everyone.
     The production of hydrogen is an increasingly common and important
 procedure in the world today.  Production of hydrogen in the U.S. alone
 currently amounts to about 3 billion cubic feet per year, with output likely
 to increase.  Uses for the produced hydrogen are varied, ranging from uses in
 welding, in production of hydrochloric acid, and for reduction of metallic
 ores.  An increasingly important use of hydrogen, however, is in the
 production of alternative fuels for machinery, such as motor vehicles.
 Successful use of hydrogen as an alternative fuel can provide substantial
 benefits to the world at large.  This is important not only in that hydrogen
 can be formed without dependence on the location of specific oils or other
 ground resources, but in that burning of hydrogen for fuel is atmospherically
 clean.  Essentially, no carbon dioxide or greenhouse gasses are produced.
 Thus, production of hydrogen as a fuel source can have great impact on the
 world at large.
     About NanoLogix
     NanoLogix, Inc., formerly known as Infectech, Inc.
 ( ), is a technology application innovator of biogas
 products and services designed to assist in worldwide energy independence and
 reduce pollution from renewable, environmentally-friendly energy sources.
 NanoLogix is also engaged in diagnostic test kits designed to be used for the
 rapid identification of infectious human diseases. The Company's patents span
 the identification and antibiotic sensitivity testing of 34 disease-producing
 bacteria, including M. tuberculosis (TB), Mycobacterium avium-intracellulare
 (MAI), pseudomonas, and nocardia. These bacteria are cited as prominent causes
 of morbidity and mortality in patients with cancer, cystic fibrosis, and AIDS.
 Additionally, NanoLogix owns a patent for the nontoxic induction of apoptosis
 in cancer cells utilizing hydrophobic hydrocarbons.
     This press release contains statements, which may constitute "forward-
 looking statements" within the meaning of the Securities Act of 1933 and the
 Securities Exchange Act of 1934, as amended by the Private Securities
 Litigation Reform Act of 1995. Those statements include statements regarding
 the intent, belief or current expectations of NanoLogix, Inc., and members of
 its management as well as the assumptions on which such statements are based.
 Prospective investors are cautioned that any such forward-looking statements
 are not guarantees of future performance and involve risks and uncertainties,
 and that actual results may differ materially from those contemplated by such
 forward-looking statements. Important factors currently known to management
 that could cause actual results to differ materially from those in forward-
 statements include fluctuation of operating results, the ability to compete
 successfully and the ability to complete before-mentioned transactions. The
 company undertakes no obligation to update or revise forward-looking
 statements to reflect changed assumptions, the occurrence of unanticipated
 events or changes to future operating results.

SOURCE NanoLogix, Inc.